Journal
CHIMIA
Volume 61, Issue 3, Pages 93-99Publisher
SWISS CHEMICAL SOC
DOI: 10.2533/chimia.2007.93
Keywords
analytics; influenza neuraminidase inhibitor; oseltamivir phosphate; production; synthesis; technical development
Categories
Ask authors/readers for more resources
The clinical development of the first orally available neuraminidase inhibitor prodrug oseltamivir phosphate (Tamiflu (TM)) proceeded very fast. In order to support this program an unprecedented team effort in chemical process research, development, piloting, production and analytics took place, which allowed the successful launch of Tamiflu (TM) in 1999, only two and a half years after it was licensed from Gilead Sciences. This article describes selected aspects of the commercially used synthesis route and a brief summary of alternative syntheses devised by Roche chemists.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available